
  • Services
    • THERAPEUTIC AREAS
      • Epilepsy & Seizure Disorders
      • Mental Illness
      • Neurodegenerative Disorders
      • Neurodevelopmental Disorders
      • Neuromuscular Disorders
      • Pain Models
      • Rare CNS Disorders
      • Injury and Trauma
    • CAPABILITIES
      • Microdyalisis
      • Biomarker Analysis
      • Pharmacokinetics & Pharmacodynamics (PK/PD)
      • Target Engagement
      • Electrophysiology
  • In Vivo AI Platforms
    • eCube™
    • NeuroCube®
    • PhenoCube®
    • SmartCube®
  • News & Insights
    • News
      • Press Releases
      • Upcoming Events
    • Insights
      • Publications
      • Posters
      • Research Updates
  • About
    • Leadership Team
    • Corporate Citizenship
    • Culture
    • Careers
  • Contact Us

Comparative psychology and the grand challenge of drug discovery in psychiatry and neurodegeneration,

by marcbacon | Jun 28, 2011

Brunner, D., Balci, F., and Ludvig, E. A. Behav Processes 2011 89, 187-195

Effect of the rd1 mutation on motor performance in R6/2 and wild type mice [Internet]. Version 28.

by marcbacon | Mar 15, 2011

Liliana M.; El-Khodor B F.; Hornberger M.; Park, Larry; Howland, David; Brunner D. PLoS Currents: Huntington Disease. 2011 Nov 29 [revised 2012 Feb 15].

Impulsive action and impulsive choice are mediated by distinct neuropharmacological substrates in rat

by marcbacon | Mar 14, 2011

Paterson N.E., Wetzler C., Hackett A., Hanania T. Int J Neuropsychopharmacol 2011

Rapid, computer vision-enabled murine screening system identifies neuropharmacological potential of two new mechanisms.

by marcbacon | Mar 10, 2011

Steven L Roberts, Filippov I.; Alexandrov V.; Hanania T.; Brunner D. Frontiers in Neuropharmacology.

Sub-optimal performance in the 5-choice serial reaction time task in rats was sensitive to methylphenidate, atomoxetine and d-amphetamine, but unaffected by the COMT inhibitor tolcapone.

by marcbacon | Mar 5, 2011

Paterson, N. E.; Ricciardi, J.; Wetzler, C.; Hanania, T. Neurosci Res 2011, 69, 41-50.
« Older Entries
Next Entries »
  • Therapeutic Areas
    • Epilepsy & Seizure Disorders
      • Preclinical Seizure Models
        • Chemical Induction Models
        • Electroshock-Induced Seizures
        • Amygdala-Induced Kindling
        • Harmaline-Induced Tremors
      • Dravet Syndrome
      • EEG Seizure
      • Angelman Syndrome
      • Rett Syndrome
      • Tuberous Sclerosis
    • Mental Illness
      • Anxiety
      • Depression
      • Schizophrenia
      • ADHD
      • Drug Abuse Liability
    • Neurodegenerative Disorders
      • Alzheimer’s Disease
      • Amyotrophic Lateral Sclerosis
      • Huntington’s Disease
      • Parkinson’s Disease
      • Spinal Muscular Atrophy (SMA)
    • Neurodevelopmental Disorders
      • ADHD Studies
      • Angelman Syndrome
      • Autism Spectrum Disorder
      • Fragile X Syndrome
      • Rett Syndrome
    • Neuromuscular Disorders
      • Amyotrophic Lateral Sclerosis
      • Charcot Marie Tooth Disease
      • Duchenne Muscular Dystrophy
      • Spinal Muscular Atrophy (SMA)
    • Pain Models
      • Acute Pain
      • Inflammatory Pain
      • Neuropathic Pain -Nerve Ligation
      • Osteoarthritis Pain Studies
      • Postoperative Pain Studies
      • PSPP Program
      • Visceral Pain
    • Rare CNS Disorders
      • Angelman Syndrome
      • Charcot Marie Tooth Disease
      • Dravet Syndrome
      • Fragile X Syndrome
      • Gaucher Disease
      • Rett Syndrome
      • Tuberous Sclerosis (TSC) Preclinical Research
    • Injury and Trauma
      • Spinal Cord Injury
      • Traumatic Brain Injury
  • Capabilities
    • Microdyalisis
    • Biomarker Analysis
      • Immunohistochemistry
      • Molecular Pharmacology
    • Pharmacokinetics & Pharmacodynamics (PK/PD)
    • Target Engagement
      • Receptor Occupancy
    • Electrophysiology
      • In vivo electrophysiology
      • Ex vivo electrophysiology
      • Compound Muscle Action Potention

Let’s Find the Right Solution Together

Our scientists are here to help you find the right model or capability for your program.

Request a Consultation

Quick Links

  • Services
  • In Vivo AI Platforms
  • News & Insights
  • About
  • Contact

Contact

Address

215 College Road
Paramus, NJ 07652

Email

info@psychogenics.com

Phone

(914) 406-8019

Fax

(914) 406-8090

© 2025 PsychoGenics Inc. All rights reserved.

  • Privacy Policy
  • Terms of Use
  • Financial Conflict of Interest Policy
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}